Oric Pharmaceuticals Inc. (ORIC) News
Filter ORIC News Items
ORIC News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
ORIC News Highlights
- For ORIC, its 30 day story count is now at 4.
- Over the past 10 days, the trend for ORIC's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- The most mentioned tickers in articles about ORIC are NOTE.
Latest ORIC News From Around the Web
Below are the latest news stories about ORIC PHARMACEUTICALS INC that investors may wish to consider to help them evaluate ORIC as an investment opportunity.
ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operational UpdatesInitial Phase 1b data for three ongoing clinical trials expected in second half of 2023: ORIC-533 in multiple myeloma, ORIC-114 in EGFR/HER2-mutated cancers, and ORIC-944 in prostate cancer Received $25 million equity investment from Pfizer, and entered into clinical development collaboration with Pfizer for a potential Phase 2 study of ORIC-533 in combination with elranatamab in multiple myeloma Cash and investments of $228.2 million expected to fund operating plan into first half of 2025 SOUTH |
6 big analyst picks: Stifel says FedEx stock is a buy | Pro RecapStifel upgraded FedEx (NYSE:FDX) to Buy from Hold and raised its price target to $222.00 from $171.00, saying there is "too much opportunity to ignore" despite execution risks. "Two significant tranches of cost savings present material potential upside to current Street estimates, even with a healthy haircut," said Stifel in a note. Stifel also noted FedEx's "rocky finish to 2022" and said macro risks remain, along with the need for "a lot of heavy lifting when it comes to operational improvement." |
ORIC Pharmaceuticals Announces Multiple Presentations at the 2023 American Association for Cancer Research (AACR) Annual MeetingORIC-944 preclinical poster presentation to highlight comprehensive biomarker strategy for ongoing Phase 1 trial in metastatic prostate cancer PLK4 poster presentation to spotlight the high selectivity required for synthetic lethality in breast cancer models SOUTH SAN FRANCISCO and SAN DIEGO, March 14, 2023 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today anno |
ORIC Pharmaceuticals to Participate in the Oppenheimer 33rd Annual Healthcare ConferenceSOUTH SAN FRANCISCO, Calif. and SAN DIEGO, March 06, 2023 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will participate in a fireside chat at the Oppenheimer 33rd Annual Healthcare Conference on Monday, March 13, 2023, at 2:00 p.m. ET. The live webcast of the discussion will be available through the investor section of the company |
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Feb. 03, 2023 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on February 1, 2023 (the “Grant Date”), ORIC granted a total of 35,596 non-qualified stock options and 5,948 restricted stock units to three new non-executive employees who began their employment with ORIC in January 2023. These inducement g |
7 Top Short-Squeeze Candidates to Watch in FebruaryFor those that want to zig while others zag, these heavily targeted stocks represent the short-squeeze candidates to watch this month. |
ORIC Pharmaceuticals to Participate in Upcoming Investor ConferencesSOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Feb. 01, 2023 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will participate in the following investor conferences in February: Guggenheim Healthcare Talks Oncology Day – Participating in a fireside chat on Wednesday, February 8, 2023, at 3:20 p.m. ET.Citi’s 2023 Virtual Oncology Leadershi |
ORIC Pharmaceuticals, Inc.'s (NASDAQ:ORIC) latest 12% decline adds to one-year losses, institutional investors may consider drastic measuresTo get a sense of who is truly in control of ORIC Pharmaceuticals, Inc. ( NASDAQ:ORIC ), it is important to understand... |
ORIC Pharmaceuticals Provides Corporate Update and Highlights Key Upcoming MilestonesInitial Phase 1b data for three ongoing clinical trials expected in second half of 2023: ORIC-533 in multiple myeloma, ORIC-114 in EGFR/HER2-mutated cancers, and ORIC-944 in prostate cancer Development candidate selected for PLK4 synthetic lethal breast cancer program Cash and investments of $228 million expected to fund operating plan into first half of 2025 SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Jan. 09, 2023 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage o |
ORIC Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare ConferenceSOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Jan. 03, 2023 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that Jacob M. Chacko, M.D., chief executive officer, will present a company overview at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023, at 11:15 a.m. PT. A live webcast of the company presentation will be available |